Sort
15,842 grants matching “pancreatic cancer”
Mesenchymal Stem Cell-Based Targeted Combined Therapy for Pancreatic Ductal Adenocarcinoma
$224,580Buddhadev Layek · North Dakota State University · P20 · FY2024 · GM
KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function
$224,506Daniel Abate-Daga · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2024 · CA
Project 6 - Development of Metabolically Active Linkers (MALs) to Improve Diagno
$224,463Jered C Garrison · University Of Nebraska Medical Center · P20 · FY2013 · GM
TGF-B RECEPTOR ALTERATIONS AND PANCREAS CANCER
$224,431University Of Texas Hlth Sci Ctr San Ant · R01 · FY2000 · CA
Translational Development of a Targeted and Stroma-breaking Nanoparticle Drug for Pancreatic Cancer Therapy
$224,425Lei Zhu · Migra-Therapeutics, Llc · R43 · FY2019 · CA
Core B â Human Biospecimen and Advanced Sequencing Core
$224,279Leonidas G Koniaris · Medical University Of South Carolina · P01 · FY2025 · CA
Full Project 2
$224,278Maurizio Pellecchia · University Of California Riverside · U54 · FY2023 · CA
NanoCytology to mitigate overdiagnosis of prostate cancer
$224,274Hariharan Subramanian · Nanocytomics, Llc · R44 · FY2015 · CA
TAS::75 0849::TAS SBIR TOPIC 307 PHASE I NOVEL IMAGING AGENTS TO EXPAND THE CLIN
$224,264Jennifer Keppler · Imaginab, Inc. · N43 · FY2011 · CA
Defining the KRAS mutation specific interactions in pancreas cancer
$224,250Guy Hobbs · Medical University Of South Carolina · P20 · FY2024 · GM
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers
$224,231Brian B Haab · Van Andel Research Institute · U01 · FY2012 · CA
Solid-Phase Platform for the Preparation of Dual-receptor Targeted PET Agents
$224,070Dexing Zeng · University Of Pittsburgh At Pittsburgh · R21 · FY2014 · EB
Molecular Studies on MUC4 Mucin Gene
$224,040Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2009 · CA
Molecular Studies on MUC4 Mucin Gene
$224,040Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2008 · CA
Molecular Studies on MUC4 Mucin Gene
$224,040Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2010 · CA
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
$223,913James K Turkson · University Of Hawaii At Manoa · R01 · FY2011 · CA
Tissue Procurement, Processing and Phenotyping Core
$223,818Maki Nakayama · University Of Colorado Denver · P30 · FY2025 · DK
Project 8 - MUC4 Nanovaccine for Pancreatic Cancer
$223,710Maneesh Jain · University Of Nebraska Medical Center · P20 · FY2013 · GM
Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH
$223,696Farhad Parhami · Max Biopharma, Inc. · R43 · FY2020 · DK
Ultra-high content analyses of circulating and solid tumor cells: A diagnostic reference system for disease burden
$223,653Michel Nederlof · Quantitative Imaging Systems, Llc · R44 · FY2021 · CA
Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors
$223,377Christopher M Heaphy · Boston Medical Center · R21 · FY2024 · CA
Pancreatic Cyst Fluid miRNOME for Biomarkers of Pancreatic Cancer
$223,369Subrata Sen · University Of Tx Md Anderson Can Ctr · R21 · FY2016 · CA
Delivering miR-29a to enhance anti-viral and anti-tumor responses in vivo
$223,343Erietta Stelekati · University Of Miami School Of Medicine · R21 · FY2025 · AI
University of Colorado Cancer Center Support Grant
$223,326Richard D Schulick · University Of Colorado Denver · P30 · FY2018 · CA
GLUTAMINE-MEDIATED TUMOR-STROMAL INTERACTION: A NOVEL TARGET FOR PANCREATIC CANCER TREATMENT
$222,984The University Of Texas Health Science Center At San Antonio · · FY2019 · Defense Health Agency